Skip to main content
TNXP
NASDAQ Life Sciences

Tonix Pharmaceuticals Secures FDA Alignment on Phase 2 Lyme Disease Prevention Study for TNX-4800

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$10.14
Mkt Cap
$159.567M
52W Low
$9.4
52W High
$69.97
52W Position info
7.9% above low
Off High info
86% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

TNXP is trading near its 52-week low of $9.4 (7.9% above the low).

Summary

Tonix Pharmaceuticals announced FDA alignment on a Phase 2 field study for TNX-4800, a Lyme disease prevention antibody, with enrollment expected to begin in Q1 2027.


Key Events · Product Development and Regulatory · TNXP

  • FDA Alignment on Phase 2 Study

    Official FDA minutes confirm alignment on an adaptive Phase 2 field study for TNX-4800, a monoclonal antibody to prevent Lyme disease, with a planned enrollment of 3,300 adults over two seasons.

  • Study Design and Endpoints

    The randomized, placebo-controlled study sets the primary efficacy endpoint as Lyme disease prevention at six months, with a key secondary endpoint at three months and safety evaluated over 52 weeks.

  • Manufacturing and Timeline

    Investigational product manufacturing remains on track for delivery to study sites in Q1 2027; the majority of enrollment is expected in the 2028 season, with a potential extension to 2029.

  • Strategic Importance

    Addressing a large unmet need — no FDA-approved Lyme disease vaccines or prophylactics exist — TNX-4800 could provide rapid, seasonal protection with a two-dose regimen.


Analysis · TNXP · Life Sciences

Receipt of official FDA minutes confirms alignment on the adaptive Phase 2 field study design for TNX-4800, a long-acting monoclonal antibody aimed at preventing Lyme disease. The trial will enroll 3,300 adults across two seasons, with the primary endpoint assessed at six months. This regulatory milestone de-risks the program and establishes a clear path toward a pivotal efficacy study, potentially addressing a large unmet need given that no Lyme disease vaccines or prophylactics are currently approved. The news carries added weight against the backdrop of a going-concern warning and cash burn — positive pipeline progress strengthens the investment thesis and could support future financing.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TNXP was trading at $10.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159.6M. The 52-week trading range was $9.40 to $69.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TNXP - Latest Insights

TNXP
Nov 13, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.99
Real-time Price: $3.07 info
Change: +$0.0792 (+3%) info
Market Cap: $58.489M info
TNXP
Nov 09, 2026, 8:25 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $3.07 info
Change: -$0.9308 (-23%) info
Market Cap: $58.489M info
TNXP
Nov 09, 2026, 7:20 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.10
Real-time Price: $3.07 info
Change: -$1.03 (-25%) info
Market Cap: $58.489M info
TNXP
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.35
Real-time Price: $3.07 info
Change: -$1.28 (-29%) info
Market Cap: $58.489M info
TNXP
Oct 27, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.36
Real-time Price: $3.07 info
Change: -$2.29 (-43%) info
Market Cap: $58.489M info